Synerbio Saccharomyces Boulardii – 30 Veg Caps
Synerbio Saccharomyces Boulardii is an expert formulation of this well researched yeast, plus four strains of friendly bacteria and added prebiotics. Ideal to take after a course of antibiotics. 100% active ingredients formulated by expert nutritionists.
Out of stock
The non-pathogenic yeast Saccharomyces boulardii was first discovered by French microbiologist, Henri Boulard in 1920 in the skin of Lychee fruit. Considered an ideal supplement to take alongside antibiotics and when travelling overseas, this remarkable yeast is one of the great success stories in probiotic therapy.
Synerbio Saccharomyces boulardii Veg Caps also includes five strains of Lactobacilli and Bifidobacteria, plus prebiotics. The unique Prebiotic FS2-60 offers full-spectrum prebiotic oligosaccharide and plant-derived inulin. FS2-60 is not digested but is utilised by the friendly flora to increase colonisation of Lactobacilli and the Bifidobacteria whilst reducing the foothold of unfriendly species.
The human gut is home to an immense population of bacteria, estimated at 39 trillion microbial cells that include bacteria, viruses and fungi. Because of the sheer size and importance of the gut bacteria, this microbial population can be viewed as a bacterial organ, about the size of your liver and just as important.
Contains 100% active ingredients formulated by expert nutritionists with no artificial fillers and no nasties. Sourced according to Viridian’s strict ethical criteria including no animal testing, GMO or palm oil.
Just to make you aware we are currently updating our packaging so your supplement may look a little different.Please don’t worry, it’s the same goodness inside.
|Saccharomyces boulardii (250mg)||5 Billion CFU|
|Synerbio viable bacteria count||1.5 Billion CFU|
|Bifido 3 strain Blend||15mg|
|Plant cellulose capsule|
|In a base of Alfalfa and Spirulina and Bilberry|
DISCLAIMER: Product information correct at the time of publication. Viridian regularly updates product formulations in order to improve product efficacy, which can result in 2 or more concurrent formulation variations in our current stock.